Literature DB >> 3517048

Analysis of epidemiologic markers of nosocomial Serratia marcescens isolates with special reference to the Grimont biotyping system.

J Sifuentes-Osornio, G M Ruiz-Palacios, D H Gröschel.   

Abstract

Seventy-one strains of Serratia marcescens obtained from hospitalized patients of the Instituto Nacional de la Nutricion in Mexico City and two Virginia hospitals (University of Virginia Medical Center and Norfolk General Hospital) were analyzed to find markers useful for the epidemiologic investigation of outbreaks with this organism. Biotyping with commercial microwell systems (API 20# system [Analytab Products, Plainview, N.Y.] and DMS Rapid NFT [DMS Laboratories, Inc., Flemington, N.J.]) was not useful. Biotyping with the system designed by Grimont (assimilation tests, pigment production, and the ability to reduce tetrathionate broth) was helpful to characterize all strains. Of the 37 Mexican strains, 36 belonged to biogroup A 5/8 and 32 were biotype A8b. The 34 strains from the Virginia hospitals were distributed among six different biogroups and 12 biotypes. Significant differences in antimicrobial susceptibility (50% MIC, microgram/ml) between Mexican and Virginia strains were seen with carbenicillin (256 versus 8), piperacillin (64 versus 4), amikacin (16 versus 2), gentamicin (2 versus 0.5), and tobramycin (16 versus 2). Some Mexican strains showed variability in the susceptibility to amikacin because they were low producers of 6'-N-acetyltransferase type I. The Mexican strains seemed to come from a hospital with cross-infection problems because most were isolated from urine, were multiresistant, and more nonpigmented; in contrast, the strains isolated at University of Virginia Medical Center represent the experience of a hospital with scattered S. marcescens infections. The Grimont biotyping scheme is a useful epidemiologic tool for the clinical microbiologist.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3517048      PMCID: PMC268618          DOI: 10.1128/jcm.23.2.230-234.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Comparison of methods for differentiating among Serratia marcescens isolated from clinical specimens.

Authors:  E Roemisch; F E Kocka
Journal:  Am J Clin Pathol       Date:  1976-07       Impact factor: 2.493

2.  Compatible results obtained from biotyping and serotyping in Serratia marcescens.

Authors:  P A Grimont; F Grimont; S Le Minor; B Davis; F Pigache
Journal:  J Clin Microbiol       Date:  1979-10       Impact factor: 5.948

3.  An outbreak of nosocomial infection due to multiply resistant Serratia marcescens: evidence of interhospital spread.

Authors:  D R Schaberg; R H Alford; R Anderson; J J Farmer; M A Melly; W Schaffner
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

4.  Biotyping of Serratia marcescens and its use in epidemiological studies.

Authors:  P A Grimont; F Grimont
Journal:  J Clin Microbiol       Date:  1978-07       Impact factor: 5.948

5.  Endemic Serratia marcescens in the Veterans Administration Hospital in Pittsburgh, Pa., 1971--1976.

Authors:  A Brown; L Davis; R B Yee; B Postic
Journal:  Health Lab Sci       Date:  1978-07

6.  The epidemiological type identification of Serratia marcescens from outbreaks of infection in hospitals.

Authors:  T L Pitt; Y J Erdman; C Bucher
Journal:  J Hyg (Lond)       Date:  1980-04

7.  Antibiotic-resistant Serratia marcescens infection in a hospital.

Authors:  R E Ambrosio; A J Van Wyk; H C De Klerk
Journal:  S Afr Med J       Date:  1979-04-07

8.  [Arabinose, melibiose and xylose oxidation and fermentation in "Serratia" (author's transl)].

Authors:  J D Piguet
Journal:  Ann Microbiol (Paris)       Date:  1978 Aug-Sep

9.  Detection of Serratia outbreaks in hospital.

Authors:  J J Farmer; B R Davis; F W Hickman; D B Presley; G P Bodey; M Negut; R A Bobo
Journal:  Lancet       Date:  1976-08-28       Impact factor: 79.321

10.  Simultaneous outbreaks of infection due to Serratia marcescens in a general hospital.

Authors:  D Coleman; F R Falkiner; M E Carr; G Dowd; G Dougan; C T Keane
Journal:  J Hosp Infect       Date:  1984-09       Impact factor: 3.926

View more
  7 in total

1.  Modification of Grimont biotyping system for epidemiologic studies with nosocomial Serratia marcescens isolates.

Authors:  J Sifuentes-Osornio; D H Gröschel
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

2.  Use of molecular typing to study the epidemiology of Serratia marcescens.

Authors:  A McGeer; D E Low; J Penner; J Ng; C Goldman; A E Simor
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

3.  Spheroplast induction in clinical isolates of Serratia marcescens in the presence of Ca2+ or Mg2+.

Authors:  Y Tada; J Yamaguchi
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

4.  Use of pulsed-field gel electrophoresis typing to study an outbreak of infection due to Serratia marcescens in a neonatal intensive care unit.

Authors:  G Miranda; C Kelly; F Solorzano; B Leanos; R Coria; J E Patterson
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

5.  Ribotyping provides efficient differentiation of nosocomial Serratia marcescens isolates in a pediatric hospital.

Authors:  E H Bingen; P Mariani-Kurkdjian; N Y Lambert-Zechovsky; P Desjardins; E Denamur; Y Aujard; E Vilmer; J Elion
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

6.  Epidemiological survey of an outbreak of multiresistant Serratia marcescens by PCR-fingerprinting.

Authors:  S B Debast; W J Melchers; A Voss; J A Hoogkamp-Korstanje; J F Meis
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

7.  Aminoglycoside resistance patterns of Serratia marcescens strains of clinical origin.

Authors:  R Coria-Jiménez; C Ortiz-Torres
Journal:  Epidemiol Infect       Date:  1994-02       Impact factor: 2.451

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.